High Expression of PAMR1 Predicts Favorable Prognosis and Inhibits Proliferation, Invasion, and Migration in Cervical Cancer

Yang, Rui; Ma, Mıngjun; Yu, Sihui; Li, Xi; Zhang, Jiawen; Wu, Sufang

doi:10.3389/fonc.2021.742017

Cited by 8 publications

(18 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thus, the quantification of gap closure showed a significant difference between stable cell lines and HT29 but not between cells overexpressing PAMR1 and Mock (Figure 7D). All these results could be explained by the insufficient quantity of PAMR1 expressed by stable cell lines compared to previous studies (Yang et al, 2021).…”

Section: Stable Overexpression Of Human Pamr1 Did Not Affect Ht29 Cel...mentioning

confidence: 53%

“…Interestingly, this downregulation arose as early as stage I (or T stage according to TNM staging) and this low amount of PAMR1 mRNA was found in all the other stages analyzed. The stage-independent decrease of PAMR1 expression in cancer raises a question if PAMR1 could be considered as an early biomarker of colorectal cancer, such as in cervical cancer (Yang et al, 2021).…”

Section: Low Pamr1 Expression In Colorectal Cancer (Crc) and In Many ...mentioning

confidence: 99%

“…Since HT29 cell line was shown to be sensitive to recombinant mouse PAMR1 when added in culture medium but not to in cellulo human PAMR1 stable overexpression, we decided to combine transfection and treatment to increase the quantity of PAMR1 in the culture medium. Same experiments were done in parallel with HeLa cells, which are cervical cancer cell lines sensitive to PAMR1 dysregulation (Yang et al, 2021).…”

Section: The Increase Of Pamr1 Quantity Significantly Reduced Cell Pr...mentioning

confidence: 99%

“…PAMR1 was first shown to be downregulated in Duchenne Muscular Dystrophy (DMD) (Nakayama et al, 2004), with no clear idea about its regenerative mechanism of action. It was also reported to be suppressed in some cancers including breast cancer (Lo et al, 2015), cervical cancer (Yang et al, 2021) and gynecologic cancer (Yu et al, 2021). Studies focusing on PAMR1 in breast cancer turned out to show that PAMR1 is downregulated by means of epigenetic silencing due to its promoter's hypermethylation (Lo et al, 2015).…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

PAMR1 negatively impacts cell proliferation and migration of Human Colon Cancer HT29 Cell Line

Haymour

Chaunavel

Assaf

et al. 2022

Preprint

View full text Add to dashboard Cite

Colorectal cancer (CRC) is becoming one of the most prevalent cancers worldwide. Among cancers, it ranks the third place in terms of incidence and the second in terms of mortality. Even though immunological test allows fast and easy diagnostic method, there is no specific and reliable methods for early detection of CRC. Despite different treatments, high risk of re-occurrence is associated with advanced and metastatic CRC stages. An exhaustive knowledge on specific biomarkers or molecular actors involved in CRC could help to eradicate tumors or limit cancer recurrence. In this study, we focused on PAMR1 (Peptidase Domain Containing Associated with Muscle Regeneration 1), which is already considered as a tumor suppressor in breast and cervical cancers. In silico analysis of RNASeq data showed that PAMR1 was significantly downregulated in CRC tissues compared to their adjacent normal ones, as well as in cervical cancer. Our analysis showed that this downregulation, probably due to promoter hypermethylation, such as in breast cancer tissues, appeared in the four cancer stages as early as the first stage. In consistency with in silico analyses, the expression of PAMR1 was found to be lower at the transcript and protein levels in CRC tissue samples compared to normal ones, as well as in different CRC cell lines (HCT116, HT29, and SW620) compared to normal colon cell line (CCD841CoN). To understand the role of PAMR1 in CRC cancer, recombinant purified PAMR1 or concentrated secretome from CHO overexpressing PAMR1 were used to exogenously treat CRC cell lines with a focus on HT-29 cells as well as Hela cervical cancer cell line known to be sensitive to PAMR1. Transient or stable transfections were also performed to determine the impact of PAMR1 overexpression in HT29 and/or HeLa cells. In this study, we finally showed that presence of PAMR1 could reduce both cell proliferation and cell migration with a positive correlation between these biological effects and PAMR1 quantity. This implies that PAMR1 expresses anti proliferative and anti migrative effects in CRC. Further studies to be done in order to confirm the tumor suppressive role of PAMR1 in CRC.

show abstract

Section: Stable Overexpression Of Human Pamr1 Did Not Affect Ht29 Cel...mentioning

confidence: 53%

Section: Low Pamr1 Expression In Colorectal Cancer (Crc) and In Many ...mentioning

confidence: 99%

Section: The Increase Of Pamr1 Quantity Significantly Reduced Cell Pr...mentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

PAMR1 negatively impacts cell proliferation and migration of Human Colon Cancer HT29 Cell Line

Haymour

Chaunavel

Assaf

et al. 2022

Preprint

View full text Add to dashboard Cite

show abstract

“…Peptidase domain containing associated with muscle regeneration 1 (PAMR1) is a tumor suppressor gene and expressed in various tissues such as skeletal muscle [39,40], brain [40], and mammary gland [39,41]. Many studies have proven that overexpression of PAMR1 markedly suppresses cell growth, especially in breast cancer [39,41], polycystic ovary syndrome [42], EC [43], and CC [40].…”

Section: Discussionmentioning

confidence: 99%

LASSO and Bioinformatics Analysis in the Identification of Key Genes for Prognostic Genes of Gynecologic Cancer

Cai

Chen

et al. 2021

JPM

View full text Add to dashboard Cite

The aim of this study is to identify potential biomarkers for early diagnosis of gynecologic cancer in order to improve survival. Cervical cancer (CC) and endometrial cancer (EC) are the most common malignant tumors of gynecologic cancer among women in the world. As the underlying molecular mechanisms in both cervical and endometrial cancer remain unclear, a comprehensive and systematic bioinformatics analysis is required. In our study, gene expression profiles of GSE9750, GES7803, GES63514, GES17025, GES115810, and GES36389 downloaded from Gene Expression Omnibus (GEO) were utilized to analyze differential gene expression between cancer and normal tissues. A total of 78 differentially expressed genes (DEGs) common to CC and EC were identified to perform the functional enrichment analyses, including gene ontology and pathway analysis. KEGG pathway analysis of 78 DEGs indicated that three main types of pathway participate in the mechanism of gynecologic cancer such as drug metabolism, signal transduction, and tumorigenesis and development. Furthermore, 20 diagnostic signatures were confirmed using the least absolute shrink and selection operator (LASSO) regression with 10-fold cross validation. Finally, we used the GEPIA2 online tool to verify the expression of 20 genes selected by the LASSO regression model. Among them, the expression of PAMR1 and SLC24A3 in tumor tissues was downregulated significantly compared to the normal tissue, and found to be statistically significant in survival rates between the CC and EC of patients (p < 0.05). The two genes have their function: (1.) PAMR1 is a tumor suppressor gene, and many studies have proven that overexpression of the gene markedly suppresses cell growth, especially in breast cancer and polycystic ovary syndrome; (2.) SLC24A3 is a sodium–calcium regulator of cells, and high SLC24A3 levels are associated with poor prognosis. In our study, the gene signatures can be used to predict CC and EC prognosis, which could provide novel clinical evidence to serve as a potential biomarker for future diagnosis and treatment.

show abstract

Identification of modules and key genes associated with breast cancer subtypes through network analysis

Mares-Quiñones,

Galán-Vásquez,

Pérez-Rueda

et al. 2024

Sci Rep

View full text Add to dashboard Cite

Breast cancer is the most common malignancy in women around the world. Intratumor and intertumoral heterogeneity persist in mammary tumors. Therefore, the identification of biomarkers is essential for the treatment of this malignancy. This study analyzed 28,143 genes expressed in 49 breast cancer cell lines using a Weighted Gene Co-expression Network Analysis to determine specific target proteins for Basal A, Basal B, Luminal A, Luminal B, and HER2 ampl breast cancer subtypes. Sixty-five modules were identified, of which five were characterized as having a high correlation with breast cancer subtypes. Genes overexpressed in the tumor were found to participate in the following mechanisms: regulation of the apoptotic process, transcriptional regulation, angiogenesis, signaling, and cellular survival. In particular, we identified the following genes, considered as hubs: IFIT3, an inhibitor of viral and cellular processes; ETS1, a transcription factor involved in cell death and tumorigenesis; ENSG00000259723 lncRNA, expressed in cancers; AL033519.3, a hypothetical gene; and TMEM86A, important for regulating keratinocyte membrane properties, considered as a key in Basal A, Basal B, Luminal A, Luminal B, and HER2 ampl breast cancer subtypes, respectively. The modules and genes identified in this work can be used to identify possible biomarkers or therapeutic targets in different breast cancer subtypes.

show abstract

High Expression of PAMR1 Predicts Favorable Prognosis and Inhibits Proliferation, Invasion, and Migration in Cervical Cancer

Cited by 8 publications

References 42 publications

PAMR1 negatively impacts cell proliferation and migration of Human Colon Cancer HT29 Cell Line

PAMR1 negatively impacts cell proliferation and migration of Human Colon Cancer HT29 Cell Line

LASSO and Bioinformatics Analysis in the Identification of Key Genes for Prognostic Genes of Gynecologic Cancer

Identification of modules and key genes associated with breast cancer subtypes through network analysis

Contact Info

Product

Resources

About